Rarebase Names Chris Moxham As Chief Executive Officer

Oct 04, 2023•almost 2 years ago

Company

Rarebase

Palo AltoBiotechnologyHealth CareTherapeuticsArtificial Intelligence

Description

Rarebase, a platform drug development biotechnology company that is revolutionizing discovering and developing medicines at unprecedented speed, scale, and capital efficiency, today announced that Chris Moxham, Ph.D., President and Chief Scientific Officer of Rarebase, has been named Chief Executive Officer effective immediately. Moxham assumes the CEO position from Rarebase co-founder Onno Faber, who has been appointed to the newly created role of Chief Technology Officer.

Company Information

Company

Rarebase

Location

Palo Alto, California, United States

About

Rarebase is enabling a better life for the 400 million people living with rare disease. With a product engine designed to discover treatments for hundreds of monogenic diseases simultaneously, Rarebase is focused on the largest untapped drug discovery opportunity in human health: rare diseases. Rarebase has already uncovered potential treatments for hundreds of rare diseases. The company has also built a “drug-gene atlas” to enable AI-driven drug discovery.

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months